Porous bioactive glass scaffolds for local drug delivery in osteomyelitis: Development and in vitro characterization

AAPS PharmSciTech

Volumn 11, Issue 4, 2010, Pages 1675-1683

  Soundrapandian, Chidambaram ^a,b   Datta, Someswar ^a   Kundu, Biswanath ^a   Basu, Debabrata ^a   Sa, Biswanath ^b  

^a CSIR CENTRAL GLASS AND CERAMIC RESEARCH INSTITUTE   (India)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

bioceramics; bone infection; drug release; organic inorganic composite; skeletal drug delivery

Indexed keywords

CHITOSAN; FLUCONAZOLE; GATIFLOXACIN; GLASS; MOLECULAR SCAFFOLD;

ARTICLE; BONE; CHEMICAL COMPOSITION; DISSOLUTION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; OSTEOMYELITIS; PRIORITY JOURNAL; SYNTHESIS; TABLET POROSITY;

ANTI-INFECTIVE AGENTS; BIOCOMPATIBLE MATERIALS; DRUG DELIVERY SYSTEMS; FLUCONAZOLE; FLUOROQUINOLONES; GLASS; HUMANS; OSTEOMYELITIS; POROSITY; SOLUBILITY;

EID: 78651475737     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9550-5     Document Type: Article

References (29)

1. C Soundrapandian S Datta B Sa 2007 Drug-eluting implants for osteomyelitis Crit Rev Ther Drug Carrier Syst 24 493 545 1:CAS:528: DC%2BD1cXjt12ntb8%3D 18298388
2. C Soundrapandian B Sa S Datta 2009 Organic-inorganic composites for bone drug delivery AAPS PharmSciTech 10 1158 71 1:CAS:528:DC%2BC3cXovVGqsbo%3D 10.1208/s12249-009-9308-0 19842042
3. SK Nandi P Mukherjee S Roy B Kundu DK De D Basu 2009 Local antibiotic delivery systems for the treatment of osteomyelitis-a review Mat Sci Eng C 29 2478 85 1:CAS:528:DC%2BD1MXht1Ggu7rM 10.1016/j.msec.2009.07.014
4. M Ouedraogo R Semde IT Some R Traore-Ouedraogo IP Guissou V Henschel, et al. 2008 Monoolein-water liquid crystalline gels of gentamicin as bioresorbable implants for the local treatment of chronic osteomyelitis: in vitro characterization Drug Dev Ind Pharm 34 753 60 1:CAS:528:DC%2BD1cXosVaisrs%3D 10.1080/03639040801926287 18627115 (Pubitemid 351962347)
5. B Kundu C Soundrapandian SK Nandi P Mukherjee N Dandapat S Roy, et al. 2010 Development of new localized drug delivery system based on ceftriaxone-sulbactam composite drug impregnated porous hydroxyapatite: a systematic approach for in vitro and in vivo animal trial Pharm Res 27 1659 76 1:CAS:528:DC%2BC3cXlvFegurY%3D 10.1007/s11095-010-0166-y 20464462
6. A Balamurugan G Balossier S Kannan J Michel AH Rebelo JM Ferreira 2007 Development and in vitro characterization of sol-gel derived CaO-P2O5-SiO2-ZnO bioglass Acta Biomater 3 255 62 1:CAS:528:DC%2BD1cXhtVCntrvN 10.1016/j.actbio.2006.09.005 17134949 (Pubitemid 46223894)
7. A Balamurugan G Balossier D Laurent-Maquin S Pina AH Rebelo J Faure, et al. 2008 An in vitro biological and anti-bacterial study on a sol-gel derived silver-incorporated bioglass system Dent Mater 24 1343 51 1:CAS:528: DC%2BD1cXpslSru7s%3D 10.1016/j.dental.2008.02.015 18405962
8. Y Zhu S Kaskel 2009 Comparison of the in vitro bioactivity and drug release property of mesoporous bioactive glasses (MBGs) and bioactive glasses (BGs) scaffolds Micropor Mesopor Mat 118 176 82 1:CAS:528:DC%2BD1cXhsFahu7%2FP 10.1016/j.micromeso.2008.08.046
9. K Czarnobaj 2008 Preparation and characterization of silica xerogels as carriers for drugs Drug Deliv 15 485 92 1:CAS:528:DC%2BD1cXht1CmsL7K 10.1080/10717540802321495 18798086
10. S Agathopoulos DU Tulyaganov JMG Ventura S Kannan A Saranti MA Karakassides, et al. 2006 Structural analysis and devitrification of glasses based on the CaO-MgO-SiO2 system with B2O3, Na2O, CaF2 and P2O5 additives J Non-Cryst Solids 352 322 8 1:CAS:528:DC%2BD28XitVensLc%3D 10.1016/j.jnoncrysol. 2005.12.003
11. H-G Bang S-J Kim S-Y Park 2008 Biocompatibility and the physical properties of bio-glass ceramics in the Na2O-CaO-SiO2-P2O5 system with CaF2 and MgF2 additives J Ceram Process Res 9 588 90
12. L Radev V Hristov B Samuneva D Ivanova 2009 Organic/inorganic bioactive materials. Part II: in vitro bioactivity of collagen-calcium phosphate silicate/wollastonite hybrids Cent Eur J Chem 7 711 20 1:CAS:528: DC%2BD1MXht1Cgu7jO 10.2478/s11532-009-0076-1
13. SK Nandi B Kundu P Mukherjee TK Mandal S Datta DK De, et al. 2009 In vitro and in vivo release of cefuroxime axetil from bioactive glass as an implantable delivery system in experimental osteomyelitis Ceram Int 35 3207 16 1:CAS:528:DC%2BD1MXhtFOku7rO 10.1016/j.ceramint.2009.05.005
14. E Kontonasaki T Zorba L Papadopoulou E Pavlidou X Chatzistavrou K Paraskevopoulos, et al. 2002 Hydroxy carbonate apatite formation on particulate bioglass in vitro as a function of time Cryst Res Technol 37 1165 71 1:CAS:528:DC%2BD38XovFOit78%3D 10.1002/1521-4079(200211)37:11<1165::AID- CRAT1165>3.0.CO;2-R
15. KA Hing 2005 Bioceramic bone graft substitutes: influence of porosity and chemistry Int J Appl Ceram Technol 2 184 99 1:CAS:528:DC%2BD2MXlsFekurk%3D 10.1111/j.1744-7402.2005.02020.x (Pubitemid 40951789)
16. F Chai JC Hornez N Blanchemain C Neut M Descamps HF Hildebrand 2007 Antibacterial activation of hydroxyapatite (HA) with controlled porosity by different antibiotics Biomol Eng 24 510 4 1:CAS:528:DC%2BD2sXhtlGiu7zE 10.1016/j.bioeng.2007.08.001 17869175 (Pubitemid 350123182)
17. Z Seeley A Bandyopadhyay S Bose 2008 Tricalcium phosphate based resorbable ceramics: influence of NaF and CaO addition Mat Sci Eng C 28 11 7 1:CAS:528:DC%2BD2sXhsVKgs7fK 10.1016/j.msec.2006.12.010 (Pubitemid 350297876)
18. R Orefice J West G LaTorre L Hench A Brennan 2010 Effect of long-term in vitro testing on the properties of bioactive glass-polysulfone composites Biomacromolecules 11 657 65 1:CAS:528:DC%2BC3cXhtFKqur0%3D 10.1021/bm901228a 20108891
19. A Balamurugan G Balossier J Michel S Kannan H Benhayoune AH Rebelo, et al. 2007 Sol gel derived SiO(2)-CaO-MgO-P(2)O(5) bioglass system-preparation and in vitro characterization J Biomed Mater Res B Appl Biomater 83 546 53 1:STN:280:DC%2BD2srps1Ohsw%3D%3D 17455268
20. NCCLS. Performance standards for antimicrobial susceptibility testing. Wayne: NCCLS; 2002.
21. W Xia J Chang 2006 Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system J Control Release 110 522 30 1:CAS:528:DC%2BD28XhtVaitbs%3D 10.1016/j.jconrel.2005.11.002 16375986 (Pubitemid 43163442)
22. L Noble AI Gray L Sadiq IF Uchegbu 1999 A non-covalently cross-linked chitosan based hydrogel Int J Pharm 192 173 82 1:CAS:528:DyaK1MXntlSmtbc%3D 10.1016/S0378-5173(99)00306-3 10567748 (Pubitemid 29531551)
23. S Rossi M Marciello G Sandri MC Bonferoni F Ferrari C Caramella 2008 Chitosan ascorbate: a chitosan salt with improved penetration enhancement properties Pharm Dev Tech 13 513 21 1:CAS:528:DC%2BD1cXht1ymsrnF 10.1080/10837450802288865
24. U Ubaidulla RK Khar FJ Ahmad P Tripathi 2009 Optimization of chitosan succinate and chitosan phthalate microspheres for oral delivery of insulin using response surface methodology Pharm Dev Tech 14 96 105 1:CAS:528: DC%2BD1MXjt1Sjuw%3D%3D 10.1080/10837450802409461
25. M Kong XG Chen CS Liu CG Liu XH Meng J Yule 2008 Antibacterial mechanism of chitosan microspheres in a solid dispersing system against E. coli Colloids Surf B: Biointerfaces. 65 197 202 1:CAS:528:DC%2BD1cXotlGjs7s%3D 10.1016/j.colsurfb.2008.04.003
26. Y Park MH Kim SC Park H Cheong MK Jang JW Nah, et al. 2008 Investigation of the antifungal activity and mechanism of action of LMWS-chitosan J Microbiol Biotechnol 18 1729 34 1:CAS:528:DC%2BD1MXotFSrsrk%3D 18955827
27. P Baldrick 2010 The safety of chitosan as a pharmaceutical excipient Regul Toxicol Pharmacol 56 290 9 1:CAS:528:DC%2BC3cXisFKitb4%3D 10.1016/j.yrtph.2009.09.015 19788905
28. AH El-Kamel MM Baddour 2007 Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation Drug Deliv 14 349 56 1:CAS:528:DC%2BD2sXovFGnt70%3D 10.1080/10717540601098716 17701524 (Pubitemid 47265817)
29. A Melville L Rodríguez-Lorenzo J Forsythe 2008 Effects of calcination temperature on the drug delivery behaviour of ibuprofen from hydroxyapatite powders J Mater Sci Mater Med 19 1187 95 1:CAS:528: DC%2BD1cXis1Wgsbw%3D 10.1007/s10856-007-3185-4 17701302 (Pubitemid 351328129)